BASILEA PHARMACEUTICA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.95 CHF | +0.23% |
|
+7.64% | +21.67% |
| May. 03 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
| Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 572M | ||||||
| 44.96B | - | |||||
| 42.65B | ||||||
| 41.85B | ||||||
| 29.04B | ||||||
| 26.08B |
